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BACKGROUND: Utilization of In Vitro Fertilization (IVF) to treat infertility is in-
creasing, despite the high cost incurred, often resulting inmultiple birthswith poor
outcomes. Physicians practicing in states with insurance mandates have been
shown to transfer fewer embryos, resulting in fewer multiple births and improved
outcomes. OBJECTIVES: The objective of this study was to compare the impact of
mandated IVF insurance coverage on the cost per live birth of healthy infants and
infants born with disability. METHODS: A Markov model was developed to calcu-
late the number of live births resulting from a maximum of six IVF cycles, and
cumulative costs through initial hospital discharge. Age-specific utilization rates,
pregnancy rates, birth rates, multiple rates, and costs for states with and without
insurance mandates were derived from the literature, insurances claims data-
bases, and publicly available CDC data. Themodel takes a societal perspective and
reports results in 2010 US dollars. RESULTS: In hypothetical cohorts of 10,000, for
women under the age of 35-years, the insurance strategy results in 42 fewer births
with disability. The non-insurance strategy results in 31 additional healthy births
but at a cost of $1,831,462 per healthy birth. For women aged 35-37, the insurance
strategy dominates the non-insurance strategy with 12 additional births with dis-
ability, and 282 additional healthy births. For women aged 38-40, the insurance
strategy dominates the non-insurance strategy with 0 additional births with dis-
ability, and 46 additional healthy births. For women aged 41-42, the insurance
strategy results in 23 fewer births with disability, and 1 fewer healthy birth. The
cost for each additional healthy birth is $244,903,064. CONCLUSIONS: This study
shows insurance coverage for IVF is a “cost-effective”, and in some age groups a
dominant strategy, even in the short time horizon from delivery through initial
discharge and should be considered for inclusion as a standard insurance benefit.
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OBJECTIVES: This study provides the results from aminimization costsmodel that
compares the use of Dienogest with the use of GnRH antagonist in women with
Endometriosis diagnosis in Colombia and Argentina. METHODS: We used a cost
minimization model. The case base are women with endometriosis diagnosis in a
1 year time horizon. For the Colombian analysis we used a public perspective while
in Argentina we used a social work perspective and a prepaid medical services
perspective. The costs used in this model are direct costs and were obtained from
some insurers of Colombian and Argentinean health system. The colombian treat-
ment schedule is: 12-month use of Dienogest vs. 6-month use of the GnRH antag-
onist, and the Argentina treatment schedule is: 12-month use of Dienogest vs
6-month use of GnRH antagonist  6-month use of supportive treatment (treat-
ment schedule 1), or 12-monthuse ofDienogest vs 9-monthuse of GnRHantagonist
 9-month use of add-back treatment  3-month use of supportive treatment
(treatment schedule 2). RESULTS: For the case base studied, we found that in
Colombia the total treatment cost is US$986.19 with Dienogest and US$2855.57
with the GnRH antagonist. In the other hand in Argentina. The total treatment cost
for the treatment schedule 1 is US$534.57 with Dienogest and US$881 with the
GnRH antagonist from the social work perspective, and $490.75with Dienogest and
812.21 the GnRH antagonist from the prepaid medical services perspective. The
total treatment cost for the treatment schedule 2 is US$534.57 with Dienogest and
US$1488.28 with the GnRH antagonist from the social work perspective, and
$490.75 with Dienogest and US$1386.21 the GnRH antagonist from the prepaid
medical services perspective. CONCLUSIONS: The use of Dienogest minimizes the
total cost either in Colombia and Argentina from any perspective.
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OBJECTIVES: In Singapore, the default option for medical care among nursing
home (NH) residents at their end of life is hospital admission, incurring high
healthcare costs. Palliative care has been shown to reduce healthcare costs at the
end-of-life; however, NHs are not equipped to offer this. Project CARE was intro-
duced in 7 NHs by a hospital unit to provide palliative care for NH residents. Our
objective is to evaluate the cost impact of Project CARE on NH residents at the
end-of-life. METHODS: Project CARE was provided to a prospective cohort identi-
fied with a risk of dying within the next 1-year. A retrospective control group
deceasedwithin 2-years prior to the inception of Project CAREwas identified. Com-
parisons between Project CARE and routine care were made for the following time
points: 1- and 3-months prior to death. We adopted the health system perspective,
including the cost incurred for palliative care visits, hospitalization length of stay
(LOS), nursing home LOS, emergency visits, specialist visits and primary care visits.
Differences in cost at 1- and 3-months prior to death were analyzed using linear
regression of log transformed cost adjusting for patient characteristics. RESULTS:
A total of 429 residents (cases: 96, controls: 333) were included for the study. Mean
age of cases and controls were 85 and 82 years respectively. At 3 months prior to
death, Project CARE cost 2.5% (95% CI: -18.2%, 23.1%) more than the routine care. A
20% (95% CI: -42%, 1.8%) savings was observed at 1 month prior to death. However,
both observations were not statistically significant. CONCLUSIONS: Costs were not
significantly different between Project CARE and routine care. High start-up cost of
the programmight have offset savings from reduction in hospitalization. We pos-
tulate potential cost savings as the program reaches full capacity.
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OBJECTIVES:High quality economic evidence is necessary for optimizing pediatric
health care allocation. The objectives were to appraise the quality of published
pediatric cost utility analyses (CUA). It was hypothesized that higher quality would
be associated with later publications, publication in a health economics/methods
journal and prospective utility assessment.METHODS: Pediatric CUAs published in
1997-2009 were assessed. Studies were retrieved from the Pediatric Economic Da-
tabase Evaluation project (PEDE), a comprehensive database of pediatric health
economic evaluations. Quality was assessed using the Pediatric Quality Appraisal
Questionnaire which scores 14 domains from 0 to 1. Higher domain scores indicate
better quality. Multiple linear regression was used to examine the effect of journal
type, whether utility was measured prospectively in the study, and year of publi-
cation on each domain score. RESULTS: There were 305 CUAs published over the
study interval. The annual number of pediatric CUAs increased over time. Most
studies were undertaken in North America and Europe. Infectious diseases and
their treatment and prevention was the most common therapeutic area (48%).
Young children (1 to 12 years old) were studied most often (39%). Utility was mea-
sured prospectively in only 8% of studies. Quality was appraised in a random sam-
ple of 213 CUAs. Mean domain scores ranged from 0.57 (Analysis) to a high of 0.91
(Target population). Studies published in methods/economics journals demon-
strated significantly higher scores for 7 domains (p0.05). Studies that measured
utility prospectively scored significantly higher on the Analysis domain. Multiple
regression results showed that quality of five domains improved over time
(p0.05). CONCLUSIONS:While quality in some domains improved over time, oth-
ers did not. Variability in quality of pediatric CUAs indicates that caution should be
exercised when interpreting results for decisionmaking. Challenges in conducting
economic evaluations in children, such as prospective utility measurement, re-
quire further research.
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OBJECTIVES:To examine in a retrospective study the incremental health care costs
of breast pain and endometrial bleeding among postmenopausal women pre-
scribed progestin containing Hormone Therapy (HT).METHODS:Women age 45 to
65 who were prescribed HT (01/01/2006-09/30/2008) were selected from a large US
claims database. The date of the first identifiedHTprescriptionwas assigned as the
index date. Patients were required to have at least 1 quarter of continuousmedical
and pharmacy benefits before and after the index date. Patients evidencing breast
pain and/or endometrial bleeding during the follow-up periodwere assigned to the
‘selected AEs’ cohort, and the remaining patients were assigned to the ‘no selected
AEs’ cohort. Patients were followed for at most 8 full quarters. A two-part model
using logistic regression and a mixed model with repeated measurements were
used in themultivariate analysis. Patients’ age,medication, procedures, andhealth
care costs during the pre-index period were adjusted in the model. Adjusted total
health care costs for each quarter, 1st and 2nd years of the follow-up period, and
average annual costs were provided. RESULTS: A total of 5,325 patients were in-
cluded in the ‘selected AEs’ cohort and 49,942 in the ‘no selected AEs’ cohort. After
adjusting for baseline differences, the adjusted quarterly costs ranged from $1944
to $2185 for the ‘selected AEs’ cohort and from $1699 to $1971 for the ‘no selected
AEs’ cohort. The quarterly health care cost differences between the two cohorts
were from $250 (p0.0001) at first quarter to $214 (p0.0001) at 8th quarter. The
adjusted annual health care costs were higher for patients with the selected AEs
($8195 vs. $7238; p0.0001).CONCLUSIONS: This study shows that the incremental
total health care costs associatedwith endometrial bleeding and breast pain are on
average $239 quarterly and $957 annually, in a US managed care setting.
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OBJECTIVES: Developed over the past 15 years, the Future Elderly Model (FEM) is a
demographic and economic model to predict future costs and health status for the
elderly. The present study updates the model by incorporating health behaviors,
which can have significant impacts on the use and value of new health care tech-
nologies. In addition, it extends the FEM to new disease areas, including: cognitive
impairment and Alzheimer’s; aging-related interventions; diabetes; socioeco-
nomic disparities; the health consequences of reimbursement for medical innova-
tions; and the productivity benefits of improved health in older populations.
METHODS:The FEMuses a representative sample of Americans aged 51, from the
Health and Retirement Study (HRS). Based on the observed risks and transitions in
the HRS, the FEM models how individuals grow old, acquire diseases and disabili-
ties, and die. The FEM is coupled with expert panels and reviews of the literature
designed to elicit the most likely scenarios for new technological changes.
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RESULTS: Nearly all the medical innovations studied will result in better health
and longer life, but they will likely increase, not decrease, Medicare spending. One
exception, however, concerns innovations that improve health behavior – e.g.,
treatments that reduce the rate of obesity. Such treatments are likely to be highly
cost-effective – in many cases costing less than $10,000 per life-year saved. Simi-
larly, prevention efforts focused on the most important risk factors for disease,
especially those requiring costly treatments, could be very cost-effective.
CONCLUSIONS: Future Medicare spending through the Baby-Boomer generation
(through 2030) will increase, despite the introduction of medical innovations that
reduce disability and improve outcomes. With the possible - but important - ex-
ception of reducing obesity, Medicare costs will dramatically increase consequent
to the overriding impact of the demographic shifts in the elderly population. Health
policy makers need to incorporate these findings in their health policy initiatives.
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OBJECTIVES: Compare clinical and economic outcomes between post-menopausal
women treated with combined estrogen and progestogen hormone therapy (HT)
within 1 and 1-2 years after diagnosis. METHODS: A retrospective analysis of
women age 45 or older from a large U.S. health plan (April 2002-September 2010)
was conducted. The first HT prescription during the identification period (April
2005-September 2008) was identified as the index date. Patients were selected if
they initiated HT treatment within 2 years of menopause diagnosis, and had 3
years of continuous health plan enrollment before (pre-period) and 2 years after
the index date (post-period). Patients with evidence of post-period pregnancy or
pre-period other HT treatment were excluded. Two cohorts were created based on
HT initiation date (Cohort A: HT initiated within 1 year of diagnosis; Cohort B: 1-2
years after diagnosis). Propensity score matching (PSM) was used to adjust for
baseline differences in age, region, procedure used, comorbidities, and healthcare
utilizations during the pre-period. RESULTS: Among 4268 eligible patients, 69.3%
(N2956) were included in Cohort A and 30.7% (N1871) in Cohort B. After PSM,
1310 patients from each group werematched. Patients prescribed HTwithin 1 year
of menopause diagnosis (Group A) were less likely to have Dual-Energy X-RAY
Absorptiometry (DEXA) scans and osteopenia than patients treated between 1-2
years after menopause diagnosis. In addition, patients with earlier treatment
showed a highermedication possession ratio (MPR) (0.49 vs. 0.46, p0.272). Health-
care costs and utilizations remained similar, except patients with early HT treat-
ment had significantly lower emergency room visit rates (22.9% vs. 26.5%, p0.033)
than patients with late HT treatment. CONCLUSIONS: Patients initiating HTwithin
1 year of menopause diagnosis had fewer comorbidities, directionally higher MPR
but not significant, and lower emergency roomvisit rates thanwomen initiatingHT
between 1-2 years. Other clinical and economic outcomes were similar.
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OBJECTIVES: To identify the potential size of the population in Canada eligible for
infertility screening as a prerequisite to publicly provided funding, and to estimate
the associated costs. METHODS: Using the Canadian Fertility Cost Model frame-
work, an age-specific decision model was developed to estimate the potential size
of theCanadian population eligible for infertility screening. Based on thenumber of
women presenting for annual comprehensive general assessments to their family
physicians, and published age-specific data on the number of women without
children, we estimated the number of Canadian couples eligible for infertility
screening. The total cost of screening was calculated using sex-specific infertility
screening costs. The potential number of live births was also estimated. Sensitivity
analyses were performed. All costs were expressed in 2009 Canadian dollars.
RESULTS: Based on the number of women who undergo an annual physician gen-
eral assessment in Canada, the number of women eligible for infertility screening
was estimated. According to published studies around 50% of infertile women
might seek medical assistance; resulting in approximately 75,000 women aged
30-45 being screened. Assuming 50% of their partners would come for screening,
37,500 males would be screened for infertility. The annual cost of screening has
been estimated at $10.6 million. The resulting number of live births would be
15,800. The proportion of total screening cost attributed to women aged 30-34,
35-39, and 40-45 is 36%, 28% and 36%, respectively. The proportion of total live
births in each age group is 51%, 31% and 18%, respectively. CONCLUSIONS: We
estimated the potential costs of infertility screening, a prerequisite to publicly
provided infertility treatments. Recent studies of selected European countries have
established that public subsidy of IVFmight represent sound fiscal policy, and that
lifetime future tax revenues over an average lifetime of an IVF offspring might
return a positive net value.
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OBJECTIVES: The objective of this study was to investigate the societal costs in
employed patients not able towork due to chronic, long-term, or terminal illness in
Germany and France for potential inclusion in health economic models and hence
influence on decision making.METHODS: Societal costs were investigated by col-
lecting and analysing labour costs, disability benefit and home care benefits in
Germany and France for employed patients. Costs were derived from publicly
available literature or databases. The costs were analysed over 1, 3 and 5 year time
horizons. RESULTS: The analysis showed that public costs could play an important
role in health economic analyses in Germany and France. Productivity loss, disabil-
ity pension and home care benefit during the first year of sickness were on average
€41,224 per employed patient in Germany. It was assumed that patients did not
work during the year at all. The societal costs were €44,952 in France per employed
patient for the first year of sickness. The year 3 per employed patient cumulative
costs in Germany and France were €144,280 and €158,464, respectively. The year 5
per employed patient cumulative costs in Germany and France were €254,205 and
€271,975, respectively. CONCLUSIONS: Societal costs associated with long term
sickness are not insignificant in Germany and France. Although indirect costs are
currently not included as part of reimbursement criteria in Germany and France,
this analysis suggests that the inclusion of these should be considered for standard
health economic analyses where possible. The results are of interest when com-
paring two treatment regimenswhere patients have differing ability to work either
during or after the treatment, or where a majority of patients are employed. The
overall perspective could support decision making beyond assessment of clinical
benefits alone.
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OBJECTIVES: Conventional pricing theory suggests that therapies with additional
benefits over an existing option may garner a higher price to account for this
incremental value/benefit. For reformulated therapies such as extended-release
(ER) products, common patient benefits (e.g. potentially reduced pill burden and
side effects) should provide enough incremental benefit to warrant a price higher
than the immediate-release (IR) formulation of the samemolecule. The objective of
this study is to quantify the intrinsic value of ER formulations by exploring the price
comparison between ER and IR formulations. METHODS: To identify therapies of
interest, a search of the Epocrates drug database was conducted and all therapies
with names indicative of reformulated products were analyzed. The price of each
ERproductwas captured for the first day ofmarket availability and compared to the
branded IR formulation. An analysis of IR generic entry and the time elapsed from
branded IR launch was conducted to determine if these confounding factors ex-
plained the observations. RESULTS: Of the 19 ER products that were analyzed, the
majority (58%) had prices lower than the IR product. Only one-quarter (26%), had
prices higher than the IR product and the remaining products had equivalent
prices. Generic entry did not correlate with the observed price comparisons be-
tween ER and IR formulations. CONCLUSIONS: The percentage price difference
between branded ER and branded IR products did not uncover a standard incre-
mental value that would indicate there is an intrinsic value provided by ER formu-
lations. An analysis of generic entry failed to show that a reduced price reference
may be a factor for products with lower ER prices. It is likely that pricing decisions
for the ER products included unique price sensitivity studies and considered con-
fidential corporate strategy, as is best practice.
INDIVIDUAL’S HEALTH – Patient-Reported Outcomes & Patient Preference
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OBJECTIVES: The purpose of this study was to compare brand and generic medi-
cation adherence in key therapeutic classes, particularly among the generic, and
the non-preferred and preferred brand initiators.METHODS: CVS Caremark phar-
macy claims data (July 1, 2008–July 1, 2011) were analyzed for patients who initi-
ated therapy at retail.We comparedmedication persistence and compliance over a
12-month period in 4 therapeutic classes: angiotensin-converting enzyme inhibi-
tors (ACEIs), angiotensin-II receptor blockers (ARBs), HMG-CoA reductase inhibi-
tors (statins), Biguanides. To qualify for the study, the patients had to be continu-
ously eligible for benefits a total of 18 months, with the additional 6 months to
identify initiators. We compared Medication Possession Ratio (MPR), Medication
Persistence, Proportion of Days Covered (PDC), and the First Fill Persistency (FFPR)
among generic, non-preferred and preferred brand utilizers, on the therapeutic
class level based on GPI-4 codes (ACEIs:3610- ARBs:3615- STATINs:3940- Bigua-
nides:2725). Bi-variate and multi-variate analyses, including linear and logistic re-
gressionwere conducted using SASVersion 9.1with SAS/STAT. RESULTS:A total of
1.1 million patients met inclusion criteria. Compared to brand utilizers, generic
utilizers’ persistency over 12-month was 3% (p0.001) higher; their adjusted 12-
months MPR was 2.65% (p0.001) higher. Generic utilizers were also 17% (p0.001)
more likely to achieve optimal adherence (MPR  80%), and were 18% (p0.001)
more likely to remain on therapy after the first fill. The utilizers of non-preferred
brands had a 1%-5% lower persistence over a 12-month period than did patients on
preferred brandmedications. Finally, thosewho started on a brand and switched to
a generic had 2-5% higher PDC, and 0.6%-2.5% (p0.001) higher 12-months persis-
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